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Malignant melanoma is a tumor known for its uncontrollable
growth and aggressive metastatic behavior. The mean sur-
vival time for patients with a metastatic melanoma is esti-
mated to be less than 6 months, tumor cells being refractory
to the conventional chemotherapy. A better understanding of
the mechanisms regulating melanoma growth and progres-
sion might help increase the number of therapeutic options
for this pathology. In this paper, we have shown that LHRH
receptors are present in the BLM melanoma cell line, both at
mRNA and at protein level; a potent LHRH agonist (LHRH-A;
Zoladex) binds to these receptors with high affinity. BLM cells
also express the mRNA for LHRH, indicating the presence of
an autocrine LHRH-based system in melanoma cells. The
treatment of BLM cells with LHRH-A dose-dependently inhib-
ited cell proliferation; this effect was found to be specific
because it was completely abrogated by the simultaneous
treatment of the cells with a LHRH antagonist. Similar ob-
servations could be obtained in another melanoma cell line
(Me15392). The activation of LHRH receptors, by means of
LHRH-A, also reduced the ability of melanoma cells to invade
a reconstituted basement membrane (Matrigel) and to mi-
grate through a Boyden’s chamber in response to a chemo-
tactic stimulus. These data represent the first report that 1)
LHRH and LHRH receptors are expressed in melanoma tumor
cells; and 2) the activation of tumor LHRH receptors reduces
both the proliferation and the metastatic potential of mela-
noma cells. It is suggested that the expression of LHRH re-
ceptors might represent a new diagnostic marker for the de-
tection and progression of melanoma. These receptors might
also be considered as a possible molecular target for a hor-
mone-based therapeutic approach to this tumor. (J Clin En-
docrinol Metab 87: 3791–3797, 2002)
MALIGNANT MELANOMA IS a tumor known for itsuncontrollable growth (1). The incidence of mela-
noma, which predominantly occurs in the skin, is increasing
dramatically (2). The prognosis of this tumor has improved
in the last decades particularly due to early diagnosis, but it
remains very poor in advanced cases, when tumor cells ac-
quire a strong potential to disseminate metastases (1). More-
over, advanced melanoma is characterized by an intrinsic
resistance to chemotherapy (3–5). A recently introduced new
chemotherapeutic drug for metastasized melanoma, temo-
zolomide, failed to offer a significant improvement of mean
survival compared with the treatment with the traditional
cytotoxic drug DTIC (dacarbazine, Bedford Laboratories,
Bedford, OH) (5). Both of these chemotherapeutics induce
thrombocytopenia as a classical side effect with considerable
risks because metastasis bleeding may occur, especially in
cerebral metastases. Due to the ability of melanoma cells to
rapidly metastasize, prevention of metastasis formation has
been indicated as the main goal in melanoma treatment (6).
Hypothalamic LHRH is the master hormone in reproduc-
tion; it controls pituitary-gonadal functions by activating LHRH
receptors present on gonadotropin-producing cells of the ad-
enohypophysis (7). LHRH agonists, when given continuously,
suppress gonadotropin synthesis and secretion through the
down-regulation of these pituitary LHRH receptors (8). This
mechanism of action has provided the rationale for the wide
and successful use of LHRH agonists in the treatment of hor-
mone-dependent tumors (e.g. prostate and breast carcinoma;
Refs. 9–11). In addition, it has been shown that these tumors
express both LHRH and LHRH receptors. Through the activa-
tion of these receptors, locally produced LHRH seems to behave
as an autocrine-negative regulator of cancer growth. Moreover,
activation of tumor LHRH receptors by exogenous LHRH ago-
nists inhibits the proliferation of tumor cells, both in vitro and
in vivo, indicating an additional and more direct antitumoral
activity for these compounds (12).
In a recent paper, van Groeninghen et al. (13) reported the
expression of LHRH receptors in glioblastoma biopsies, sug-
gesting that these binding sites might represent a diagnostic
marker, and possibly a new therapeutical target, for nervous
system tumors. On the basis of the observation that malignant
gliomas and malignant melanomas are both tumors of neuro-
ectodermal origin, we decided to verifiy whether a LHRH-
based system (LHRH and the respective receptors), similar to
that previously described in tumors of the reproductive tract, is
expressed in melanoma cells. We also investigated whether the
activation of this system might affect the proliferation rate as
well as the metastatic properties of this tumor.
Materials and Methods
Materials
The LHRH agonist (LHRH-A) Zoladex (d-Ser(tBu)6Aza-Gly10-
LHRH) was kindly provided by AstraZeneca Pharmaceuticals, Divi-
Abbreviations: ANT, LHRH antagonist; FBS, fetal bovine serum;
LHRH-A, LHRH agonist.
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sione Farmaceutici (Milano, Italy). The LHRH-antagonist Antide (ANT,
acetyl--[2.Naphtyl]-d-Ala-d-p-chloro-Phe--[3-pyridyl]-d-Ala-Ser-N-
[Nicotinoyl]-Lys-N-[Nicotinoyl]-d-Lys-Leu-N-[Isopropyl]-Lys-Pro-d-
Ala-NH2) was purchased from Sigma Chemical Co. (St. Louis, MO).
Cell cultures
The human melanoma BLM and Me15392 cell lines, both possessing
high proliferative and metastatic potential (14), were kindly donated by
Dr. Van Muijen (Department of Pathology, University Hospital Nijme-
gen, The Netherlands) and Dr. Parmiani (Istituto Nazionale per lo Studio
e la Cura dei Tumori, Milano, Italy), respectively. BLM cells were grown
in DMEM medium (Seromed, Biochrom KG, Berlin, Germany), whereas
Me15392 cells were grown in RPMI medium (Seromed). In both cases,
cell culture media were supplemented with 10% fetal bovine serum (FBS,
Life Technologies, Inc., Paisley, Scotland), glutamine (1 mm), antibiotics
(100 IU/ml penicillin G sodium, 100 g/ml streptomycin sulfate), and
sodium pyruvate (100 mm) in a humidified atmosphere of 5% CO2/95%
air. The human androgen-independent DU 145 prostate cancer cell line
was obtained from American Type Culture Collection (Rockville, MD).
This cell line has been used as a positive control, because we have
previously shown that a LHRH system (LHRH and LHRH receptors) is
expressed in these cells (15, 16).
RT-PCR analysis of LHRH and LHRH receptor mRNA
Total RNA from BLM cells (as well as from DU 145 cells, used as
positive control) was prepared according to a modification of the gua-
nidium thiocyanate/cesium chloride method (17). RNA (2 g) was used
in a RT reaction. cDNA synthesis was performed using the Gene AMP
kit (Perkin Elmer Cetus, Norwalk, CT), with an oligo(dT)16 as a primer
for the RT. Samples containing cDNAs obtained from prostate tumor
cells were then amplified in a 100-l solution containing PCR buffer (50
mm KCl, 10 mm Tris-HCl), 2 mm MgCl2, 2.5 U Taq polymerase. For
LHRH cDNA amplification, PCR was performed for 35 cycles (1-min
denaturation at 94 C, 30-sec primer annealing at 60 C, and 2-min primer
extension at 72 C) in the presence of the primers: 5-TGGTGCGTG-
GAAGGCTGCTC-3 (sense, 78/97, 20 pmol) and 5-CTTCTTCTGC-
CCAGTTTCCTC-3 (antisense, 285/305, 20 pmol; Ref. 18). For the am-
plification of LHRH receptor cDNA, PCR was performed for 35 cycles
(1-min denaturation at 94 C, 1-min primer annealing at 50 C, and 2-min
primer extension at 72 C) in the presence of the following primers:
5-GCTTGAAGCTCTGTCCTGGGA-3 (sense,25 to5, 30 pmol) and
5-CCTAGGACATAGTAGGG-3 (antisense, 844–860, 30 pmol; Ref. 19).
Both pairs of primers have been used previously in our laboratory to
amplify LHRH and LHRH receptor cDNAs in prostate cancer cells (15,
16, 20). The predicted amplified cDNA fragments were 228 and 885 bp
for LHRH and LHRH receptor, respectively. After PCR, the amplified
cDNA products were separated on 1.5% agarose gels and stained with
ethidium bromide. After Southern blotting, blots were hybridized with
synthetic 32P-labeled oligonucleotide probes, specific for the LHRH and
LHRH receptor cDNAs, as previously described (15, 16).
Western blot analysis of the LHRH receptor
Membrane fractions were prepared from BLM and Me15392 cells (as
well as from DU 145 cells, used as positive controls) according to the
protocol reported by Limonta et al. (16). Samples were homogenized in
10 mm Tris-HCl (pH 7.6) buffer containing 1 mm dithiothreitol on ice.
The homogenates were centrifuged two times for 10 min each at 800 
g to remove cellular debris, and the resulting supernatants were cen-
trifuged at 18,000 g to pellet down the membrane fractions. The pellets
were solubilized in RIPA buffer [50 mm Tris-HCl (pH 7.7), 150 mm NaCl,
0.8% Triton X-100, 0.8% sodium deoxycholate, 0.08% SDS, 10 mm eth-
ylendiamine tetraacetate, 100 m Na3VO4, 50 mm NaF, 0.3 mm phenyl-
methylsulfonylfluoride, and 5 mm iodoacetic acid] and electrophoresed
on 10% polyacrylamide gel under reducing conditions. Proteins were
transferred onto a nitrocellulose filter. Filters were probed with the F1G4
monoclonal antibody (15 g/ml), for 2 h at room temperature. This
antibody has been raised against the human pituitary LHRH receptor
(kindly provided by Dr. A. A. Karande, Department of Biochemistry,
Indian Institute of Science, Bangalore, India). Filters were then incubated
for 1 h at room temperatrure, with an antimouse IgG (1:100,000; Santa
Cruz Biotechnology, Inc., Santa Cruz, CA). Antibody bound to the
LHRH receptor was detected with the ECL-Western blotting detection
system after a 5- to 10-min exposure to a Hyperfilm-ECL x-ray film
(Amersham Pharmacia Biotech, Milano, Italy) at room temperature (21).
The specificity of F1G4 antibody for the human pituitary LHRH receptor
has been previously demonstrated (16, 22).
LHRH receptor assay
The binding assay for LHRH receptors in melanoma cells has been
performed as previously described (15) by using 125I-LHRH-A (specific
activity, 800-1000 Ci/g) as the specific ligand. Briefly, displacement
curves were performed by incubating 100-l cell membrane aliquots
with 125I-LHRH-A (200,000 cpm) in either the absence or the presence
of increasing concentrations of unlabeled LHRH-A (1011-107 m). Non-
specific binding was determined in the presence of 105 m unlabeled
LHRH-A. Displacement curves allowed the determination of binding
characteristics for LHRH receptors (Kd, dissociation constant; Bmax, max-
imum concentration of binding sites) on BLM and Me15392 melanoma
cells. LHRH receptors have also been analyzed on rat pituitary mem-
branes used as controls. Four displacement curves have been performed
for each experimental group. The protein content of each membrane
preparation was evaluated according to the method of Bradford (23).
Cell proliferation studies
BLM cells were plated at a density of 700 cells/cm2 in 10-mm dishes
in culture medium. Cells were allowed to attach and start growing for
3 d; the seeding media were then changed. Cells were treated daily (the
drug was added to the medium every day), for 7 d with LHRH-A
(1011-106 m); the medium was changed every 2 d. At the end of the
treatment, cells were collected and counted by hemocytometer.
To confirm the specificity of the action of LHRH-A on melanoma cell
proliferation, we investigated whether the effects of the LHRH agonist
might be counteracted by a potent LHRH antagonist. A preliminary
experiment was performed to select the dose of the LHRH anatgonist
(ANT) to be used. To this purpose, BLM cells were treated daily with
ANT at different doses (1011-106 m). Cells were harvested and counted
after 7 d of treatment. Subsequently, BLM cells were treated daily, for
7 d, with LHRH-A (107 m), in either the absence or the presence of ANT
(107 m). Cells were counted 7 d after the beginning of the treatment.
The antiproliferative action of LHRH agonists on melanoma cells has
been further investigated in another melanoma cell line (Me15392).
These experiments have been performed as described above for BLM
cells (same LHRH-A, same doses of the drug, and same length of treat-
ment, etc.).
All proliferation experiments were performed in four to six replicates.
The data obtained from three independent experiments were analyzed
according to the Dunnett’s test after one-way ANOVA (24).
Matrigel gel assay
For invasion and migration experiments, the 106 m dose of LHRH-A
has been chosen because it was the most effective in proliferation studies.
This dose has also been used in previous papers from our laboratory
analyzing the interaction between LHRH agonists and stimulatory
growth factors in prostate cancer cells (25, 26).
Subconfluent BLM cells were collected by trypsinization, resus-
pended in culture medium, and seeded in 20 l (150,000 cells/drop) on
the lid of a culture dish. The lid was then placed on a dish filled with
2 ml of culture medium and incubated at 37 C for 48 h. Matrigel solution
(80 l, 2.7 mg/ml) was pipetted onto the bottom of wells of a 24-well
culture dish and left to set at 37 C. Cell aggregates were transferred over
the cushion and then overlaid with additional 20 l of Matrigel. The
aggregates into Matrigel were covered with 400-l culture medium in
the absence or in the presence of LHRH-A (106 m). The aggregates were
then observed daily under a light microscope, and at the end of the
incubation time phase-contrast pictures of the aggregates were taken.
Chemomigration assay
The assay was performed using a 48-well Boyden’s chamber, accord-
ing to the manufacturer’s instruction (Neuroprobe, Cabin John, MD).
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Subconfluent BLM cells, grown in culture medium, were pretreated for
5 d with LHRH-A (106 m) and harvested at the end of the treatment.
BLM cell suspensions (105 cells/50 l), resuspended in culture medium
deprived of FBS, were placed in the open-bottom wells of the upper
compartment of the chamber. Each pair of wells was separated by
polyvinylpyrrolidone-free polycarbonate porous membrane (8-m
pores) precoated with gelatin (0.2 mg/ml in PBS). The chemoattractant
(FBS 5%) was placed in the lower compartment of the chamber. The
chamber was then kept for 4 h in the cell culture incubator. After that,
the cells migrated through the pores and adhered to the underside of the
membrane; they were fixed, stained (Diff-Quick kit, DADE, Dudingen,
Switzerland), and mounted onto glass slides. For quantitative analysis,
six random objective fields of stained cells were counted for each well
(8 wells/experimental group) and the mean number of migrating cells
per square millimeter was calculated. The data obtained from four
independent experiments were compared by ANOVA and Dunnett’s
test (24).
Results
Expression of LHRH and the LHRH receptor in BLM
melanoma cells
The expression of LHRH and LHRH receptor mRNA in
melanoma BLM cells was investigated by RT-PCR. After
PCR, the amplified cDNAs were electrophoresed on a 1.5%
agarose gel containing ethidium bromide. With regard to the
expression of LHRH, the predicted 228-bp fragment was
observed in BLM cells (Fig. 1, top, lane 1) as well as in prostate
cancer cells used as controls (Fig. 1, top, lane 2). No cDNA
band was detected in samples without RT (data not shown),
ruling out the possibility of genomic DNA contamination.
After Southern blotting, the cDNA fragments, obtained from
BLM and prostate cancer cells, hybridized with the 32P-
labeled oligonucleotide probe specific for LHRH cDNA (Fig.
1, bottom, lanes 1 and 2).
In the case of the expression of the LHRH receptor mRNA,
the results obtained demonstrated that the predicted 885-bp
cDNA fragment could be obtained in BLM (Fig. 2, top, lane
1), as well as in prostate cancer cells (Fig. 2, top, lane 2). No
cDNA band was amplified in samples without RT (data not
shown). As expected, the LHRH receptor cDNA bands hy-
bridized with the specific 32P-labeled oligonucleotide probe
specific for LHRH receptor cDNA (Fig. 2, bottom, lanes 1 and 2).
The presence of LHRH receptors in melanoma cells has
been further investigated at the protein level by Western
blotting technique and by using the F1G4 monoclonal anti-
body specifically raised against the human pituitary LHRH
receptor. As shown in Fig. 3, a major protein band of ap-
proximately 64-kDa molecular mass was identified by the
antibody in BLM cells (lane 1) as in prostate cancer cells (Fig.
3, lane 2). This molecular mass corresponds to that previ-
ously reported for the human pituitary LHRH receptor (27).
The level of expression of this receptor was not found to be
affected by a 7-d treatment with the LHRH agonist (data not
shown).
Effect of LHRH agonists on the proliferation of BLM
melanoma cells
The observation that both LHRH and LHRH receptors are
expressed in BLM cells prompted us to investigate whether
this LHRH-based system might be involved in the local con-
trol of melanoma cell growth. To this purpose, BLM cells
were treated daily, for 7 d, with the potent LHRH agonist
LHRH-A (1011-106 m). The treatment resulted in a signif-
icant and dose-dependent inhibition of cell proliferation
(Fig. 4).
Further studies were performed to evaluate whether the
antiproliferative action of LHRH-A on melanoma cells could
be antagonized by the simultaneous treatment of the cells
FIG. 2. RT-PCR analysis of the expression of the LHRH receptor in
BLM cells. Top, Ethidium bromide-stained agarose gel of the ampli-
fied cDNAs. Bottom, Autoradiography of the Southern blot obtained
from the gel shown in the top panel after hybridization with a 32P-
labeled oligonucleotide LHRH receptor cDNA probe. Lane 1, BLM
cells; lane 2, prostate cancer cells; lane 3, RT-PCR control (308 bp).
One of three experiments performed is reported.
FIG. 1. RT-PCR analysis of the expression of LHRH in BLM cells.
Top, Ethidium bromide-stained agarose gel of the amplified cDNAs.
Bottom, Autoradiography of the Southern blot obtained from the gel
shown in the top panel after hybridization with a 32P-labeled oligo-
nucleotide LHRH cDNA probe. Lane 1, BLM cells; lane 2, prostate
cancer cells; lane 3, RT-PCR control (308 bp). One of three experi-
ments performed is reported.
FIG. 3. Western blot analysis of solubilized membrane proteins from
BLM cells (lane 1) and prostate cancer cells (lane 2), probed with the
F1G4 monoclonal antibody raised against the human pituitary LHRH
receptor. One experiment representative of three is reported.
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with the LHRH anatagonist ANT. In preliminary experi-
ments, the activity of ANT was evaluated. Figure 5A shows
that the antagonist did not affect the proliferation of the cells,
when given at the doses 1011-107 m. The compound re-
duced slightly, but not significantly, the growth of BLM cells
at the dose of 106 m. For subsequent experiments, the dose
of 107 m was then selected. Figure 5B confirms that ANT
(107 m), when given alone, has no effect on cell proliferation;
on the other hand, ANT totally blocked the antiproliferative
action exhibited by LHRH-A.
Expression and possible role of LHRH receptors in Me15392
melanoma cells
The presence of LHRH receptors and their possible role in
the control of melanoma cell proliferation have been further
investigated in an additional melanoma cell line (Me15392).
By Western blot analysis and by using the F1G4 monoclonal
antibody, we demonstrated that a protein band of 64 kDa was
present in membrane preparations from Me15392 cells (Fig.
6A, lane 2). The molecular mass of this band corresponded
to that found in BLM cells (Fig. 6A, lane 1).
As in the case of BLM cells, the treatment of Me15392 cells
with LHRH-A (1011-106 m), for 7 d, resulted in a significant
and dose-dependent inhibition of cell proliferation (Fig. 6B).
Binding parameters of LHRH receptors in BLM and
Me15392 melanoma cells
LHRH receptors in melanoma cells have been analyzed
also in terms of binding parameters. Binding sites for 125I-
LHRH-A have been found to be present on the membranes
of both BLM and Me15392 cells. Computer analysis of the
data obtained from the displacement curves revealed the
presence of a single class of high-affinity binding sites (Kd in
the nanomolar range) in both melanoma cell lines, as well as
in rat pituitaries used as controls (Table 1). This observation
agrees with previous data showing the expression of high-
affinity LHRH receptors in tumors of the reproductive tract
(28, 29).
FIG. 4. Effects of the LHRH agonist (LHRH-A) on the proliferation of
BLM cells. Results are expressed as mean cell number per plate SE.
*, P  0.05 vs. controls (C).
FIG. 5. A, Effects of the LHRH antagonist (ANT) on the proliferation
of BLM cells. B, Effects of the LHRH antagonist (ANT, 107 M) on the
inhibition of BLM cell proliferation induced by the LHRH agonist
(LHRH-A, 107 M). Results are expressed as mean cell number per
plate  SE. *, P  0.05 vs. controls without drugs (C).
FIG. 6. A, Western blot analysis of the expression of the LHRH re-
ceptor in Me15392 cells. Lane 1, BLM cells; lane 2, Me15392 cells. B,
Effects of the LHRH agonist (LHRH-A) on the proliferation of Me
15392 cells. Results are expressed as mean cell number per plate 
SE. *, P  0.05 vs. controls (C).
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Effect of LHRH agonists on the metastatic potential of BLM
melanoma cells
These experiments have been performed to verify whether
the activation of locally expressed LHRH receptors might
affect the metastatic potential of melanoma cells. First, we
studied the effects of the LHRH agonist LHRH-A (106 m) on
the ability of BLM cells to invade a matrix of a reconstituted
basement membrane (Matrigel). BLM cells spontaneously
form cell aggregates in Matrigel, when prepared by the hang-
ing-drop technique. Figure 7 shows that BLM cells actively
leave the aggregate and invade the Matrigel preparation at
4, 8, and 12 d. The treatment of BLM cells with Zoladex
completely abrogated the migration of the cells through the
Matrigel at all time intervals considered (Fig. 7).
We then analyzed whether LHRH agonists might affect
the ability of melanoma cells to migrate toward a chemoat-
tractant, using the Boyden’s chamber technique and FBS 5%
as the chemotactic stimulus. We observed that, when BLM
cells were pretreated with Zoladex (106 m) for 5 d, the
number of the cells that migrated in response to the che-
moattractant was significantly decreased when compared
with control cells (Fig. 8).
Discussion
These results demonstrate that both LHRH and LHRH
receptors are expressed in human melanoma cells in culture
(BLM and Me15392). This unexpectedly discovered auto-
crine LHRH system seems to participate in the mechanisms
regulating cell proliferation exerting an inhibitory activity,
because LHRH receptor activation by an exogenous LHRH
agonist brings about a significant decrease of tumor cell
proliferation. The inhibitory effect of the LHRH agonist is
specific because it is counteracted by the simultaneous treat-
ment of the cells with a LHRH antagonist. It is well known
that malignant transformation of normal melanocytes into
melanoma cells is characterized, as in other tumors, by a
gradual decrease of the dependency on external mitogenic
stimuli (30), accompanied by a simultaneous acquisition of
an increased expression of multiple growth factors (31, 32).
The data reported here indicate that, in addition to growth
stimulatory factors, melanoma cells may also express a
LHRH-based system, endowed with inhibitory activities.
Consequently, melanoma growth and progression may pos-
sibly be viewed as the result of the algebraic sum of positive
and negative regulators. The activation of the inhibitory sys-
tem, through the use of LHRH agonists, may reduce tumor
growth and interfere with the positive effect of the mitogenic
factors.
The mechanism of the antitumor activity of LHRH ago-
nists on melanoma cells is still unclear. Because the treatment
of the cells with LHRH-A does not affect the level of expres-
sion of LHRH receptors, it seems unlikely that it might be
related to a receptor down-regulation. Alternatively, LHRH
agonists might act by interfering with the activity of locally
produced growth stimulatory factors, as previously de-
scribed for hormone-related tumors (25, 26, 33).
So far, a direct oncostatic activity of LHRH agonists has
been reported only for tumors related to the reproductive
system. We have previously demonstrated that LHRH an-
alogs inhibit the growth of prostate cancer cells, both in vitro
(15, 20, 34) and in vivo (35), through the activation of locally
expressed LHRH receptors. Similar observations have been
TABLE 1. Characteristics of 125I-LHRH-A binding to human
melanoma cell membranes
Dissociation constant
(Kd)
125I-LHRH-A binding
capacity (fmoles/mg protein)
BLM cells 0.7–1.1 nM 150–200
Me15392 cells 0.1–0.6 nM 200–250
Rat pituitaries 1.5–2.0 nM 70–100
Binding characteristics were evaluated from displacement curves
as described in Materials and Methods.
FIG. 7. Effects of the LHRH agonist (LHRH-A) on the capacity of
BLM melanoma cells to invade a reconstituted basement membrane
after 4, 8, and 12 d of treatment. Results from one of four experiments
performed are reported. Scale bar, 700 m.
FIG. 8. Effects of the LHRH agonist (LHRH-A) on the ability of BLM
melanoma cells to migrate toward a chemotactic stimulus (FBS 5%).
*, P  0.01 vs. controls (C).
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reported for tumors of the female reproductive system (36–
42). It is well known that LHRH agonists, given either alone
or in combination with antisteroidal agents (9–11), are
widely and successfully used for the treatment of hormone-
dependent tumors. The anticancer activity of LHRH agonists
is mainly based on their ability to suppress the pituitary-
gonadal function through the down-regulation of LHRH
receptors on gonadotrops. The demonstration of an addi-
tional and more direct inhibitory activity of LHRH agonists
on steroid-dependent cancer cells has given further support
to their clinical application.
The results here reported seem to indicate that LHRH
agonists might also exert an antitumor activity in melanoma,
a tumor that is not usually included in the list of hormone-
related cancers. Another interesting finding of this study is
that LHRH agonists significantly reduce the ability of mel-
anoma cells to invade a reconstituted basement membrane
and to migrate in response to a chemotactic stimulus. To our
knowledge, this is the first time that such an activity is re-
ported for LHRH agonists. It is well known that the main
reason for the inefficacy of the clinical treatment of mela-
noma, in addition to its intrinsic resistance to chemotherapy,
is due to its strong ability to rapidly metastasize into target
tissues (6). The present results seem to suggest that, in ad-
dition to a direct antitumor activity, LHRH agonists might
also reduce the metastatic potential of melanoma cells. Fur-
ther studies are in progress in our laboratory to clarify the
mechanism of this antimetastatic activity.
Taken together, the findings here reported might open the
way to innovative therapies for skin cancer, aimed at inhibiting
both tumor growth and tumor metastastatic behavior. Clini-
cally available LHRH agonists are safe, well tolerated, and have
no side effects. However, it must be pointed out that the con-
ventional LHRH agonist preparations have been designed to
suppress the pituitary-gonadal functions in which LHRH re-
ceptors are present in high concentrations. Therefore, the ques-
tion of a direct activity of LHRH agonists on tumor cells has
been raised. The elucidation of the concentrations of LHRH
agonists that might be required in tumor tissues to induce their
antiproliferative action might help clarify this issue. This might
lead to the development of pharmaceutical formulations or
alternative routes of administration to provide the optimal con-
centration of LHRH agonists at the level of the tumor.
In conclusion, this study represents the first scientific re-
port of a LHRH-based growth inhibitory system present in
malignant melanoma cells. This result looks very intriguing
for three reasons. First, the finding reveals a new molecular
mechanism of autocrine control of melanoma cell prolifer-
ation. Second, LHRH receptor activation by means of LHRH
agonists significantly inhibits not only the proliferation but
also the metastatic potential of melanoma cells. Third, the
LHRH receptor might represent a new diagnostic marker for
the detection of skin tumors.
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